C3.ai, Inc. (AI)
NYSE: AI · Real-Time Price · USD
10.30
-0.35 (-3.29%)
Sep 28, 2026, 2:00 PM EDT - Market open
C3.ai Revenue
C3.ai had revenue of $52.38M in the quarter ending July 31, 2026, a decrease of -25.46%. This brings the company's revenue in the last twelve months to $232.38M, down -37.55% year-over-year. In the fiscal year ending April 30, 2026, C3.ai had annual revenue of $250.27M, down -35.67%.
Revenue (ttm)
$232.38M
Revenue Growth
-37.55%
P/S Ratio
7.37
Revenue / Employee
$304,165
Employees
764
Market Cap
1.66B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2026 | 250.27M | -138.79M | -35.67% |
| Apr 30, 2025 | 389.06M | 78.47M | 25.27% |
| Apr 30, 2024 | 310.58M | 43.79M | 16.41% |
| Apr 30, 2023 | 266.80M | 14.04M | 5.55% |
| Apr 30, 2022 | 252.76M | 69.54M | 37.96% |
| Apr 30, 2021 | 183.22M | 26.55M | 16.95% |
| Apr 30, 2020 | 156.67M | 65.06M | 71.02% |
| Apr 30, 2019 | 91.61M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GigaCloud Technology | 1.47B |
| Pagaya Technologies | 1.39B |
| Calix | 1.11B |
| Progress Software | 1.00B |
| EVERTEC | 996.16M |
| Bandwidth | 828.24M |
| Flywire | 713.54M |
| Marqeta | 677.21M |
AI News
- 25 days ago - C3.ai Earnings Call Transcript: Q1 2027 - Transcripts
- 25 days ago - C3.ai Earnings release: Q1 2027 - Filings
- 25 days ago - C3.ai Quarterly report: Q1 2027 - Filings
- 25 days ago - C3 AI Announces Fiscal First Quarter 2027 Results - Business Wire
- 4 weeks ago - C3.ai Proxy statement: Proxy filing - Filings
- 4 weeks ago - C3.ai Proxy statement: Proxy filing - Filings
- 5 weeks ago - C3 AI to Announce Financial Results for Fiscal First Quarter 2027 on September 2, 2026 - Business Wire
- 5 weeks ago - Longevica Therapeutics Appoints Ex-Genentech Biotech Veteran Dr. Prasun Mishra as CEO to Advance World's Largest $13 Million Mammalian Longevity Study Toward Clinical Development - Business Wire